Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000402306 | DOI Listing |
Cancer
October 2011
Department of Medical Sciences, Endocrine Oncology, Uppsala University, Sweden.
Background: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin and etoposide is frequently used as first-line palliative chemotherapy. There are, however, no published studies concerning second-line treatment of the disease.
View Article and Find Full Text PDFFortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd
February 1977
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!